MediciNova Shares Tumble After NAFLD Drug Misses Primary Trial Endpoints

MediciNova Inc. (NASDAQ: MNOV) shares plunged in pre-market trading after the biopharmaceutical company announced that its Phase 2 trial for the drug candidate tipelukast (MN-001) failed to meet its co-primary endpoints.

Trial Data Disappoints

The company released topline data from its randomized, double-blind, placebo-controlled study involving 40 patients with non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia associated with type 2 diabetes. While the results showed some positive signals, they ultimately fell short of the trial's main objectives.

Key findings from the 24-week study include:

• Missed Primary Endpoints: The drug did not produce a statistically significant reduction in serum triglycerides, liver fat content, or body weight at the critical 24-week mark compared to placebo.
• Early Positive Signal: Tipelukast did achieve a statistically significant reduction in serum triglycerides at Week 4.
• Other Improvements: The data also showed improvements in HDL cholesterol and HDL particle concentration.

Ad

Despite the early positive data point, the failure to meet the two main long-term goals of the study has raised significant questions about the drug’s efficacy and commercial viability for this indication.

Market Reaction and Headwinds

In response to the disappointing readout, MediciNova's stock fell 8.9% in pre-open trading. The negative reaction from investors reflects the criticality of meeting primary endpoints in clinical trials, which are key milestones for drug development.

The sell-off was amplified by a challenging macroeconomic environment. Broader market indices were also down amid rising Treasury yields and crude oil prices, creating a risk-off posture among investors. This sentiment is often particularly punishing for clinical-stage biotechnology companies, which are viewed as higher-risk investments.